BMY Stock: Analysts See 16% Upside and a Strong Buy

1 month ago 22

Vandita Jadeja

Mon, April 20, 2026 astatine 9:50 AM CDT 5 min read

Bristol Myers Squibb (BMY) posted Q4 2025 gross of $12.5B (beating estimates by 1.68%) with Growth Portfolio gross reaching $7.39B, up 16% year-over-year and present 50% of full revenue, portion Breyanzi grew 49%, Camzyos 59%, and Opdualag 38% successful the quarter.
Bristol Myers Squibb’s pipeline has aggregate pivotal readouts expected successful the backmost fractional of 2026, including Iberdomide FDA determination successful August and Milvexian changeable prevention proceedings results, positioning the institution for imaginable industry-leading maturation into the 2030s contempt bequest merchandise erosion and $49B indebtedness load.
The expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks. Get them present FREE.

Bristol-Myers Squibb (NYSE:BMY) trades astatine $60.17 arsenic of writing. The 24/7 Wall St. Price Target is $70.12, implying upside of 16.51% implicit the adjacent 12 months. The 24/7 Wall St. exemplary standing is buy, with a precocious (90%) assurance level.

Metric

Value

Current Price	$60.17
24/7 Wall St. Price Target	$70.12
Upside/Downside	+16.51%
Model Rating	BUY
Confidence Level	90%

Bristol-Myers Squibb is simply a large-cap pharmaceutical institution successful portfolio transition. Its Growth Portfolio is accelerating, its pipeline is unusually active, and the banal trades astatine a guardant net aggregate that looks undemanding comparative to peers.

BMY has outperformed the broader marketplace year-to-date successful 2026, up 11.76% YTD versus 2.89% for the S&P 500. Over the past 12 months, BMY roseate 25.44% versus 33.48% for the S&P 500. The banal sits adjacent to its 52-week precocious of $62.25, having recovered from a 52-week debased of $41.46.

READ: The expert who called NVIDIA successful 2010 just named his apical 10 AI stocks

Q4 2025 net produced a header EPS miss of $1.26 reported versus the $1.63 estimate, a 22.70% miss, driven by a $1.39 cardinal Acquired IPRD complaint tied to the Orbital Therapeutics acquisition that depressed EPS by astir $0.60 per share.

Revenue told a amended story: $12.5 billion, beating estimates by 1.68%. Full-year 2025 non-GAAP EPS came successful astatine $6.15, beating the $6.11 estimation by 0.58%. The marketplace responded positively, with the banal rising 3.3% connected net day.

The bull lawsuit centers connected the Growth Portfolio and a catalyst-rich pipeline. Growth Portfolio gross reached $7.39 cardinal successful Q4 2025, up 16% year-over-year, present representing much than 50% of full revenue. Breyanzi grew 49%, Camzyos 59%, and Opdualag 38% successful Q4. Eliquis, the largest product, guided for 10-15% worldwide gross maturation successful 2026.

Pipeline catalysts are stacked crossed the backmost fractional of 2026. Iberdomide carries an FDA precedence reappraisal with a determination expected successful August 2026. Milvexian is successful pivotal AF and changeable prevention trials. Admilparant has pivotal IPF information expected successful 2026. Cobenfy is advancing successful Alzheimer's Disease Psychosis.

Read Entire Article